- Home
- BRW vs EBS Comparison
BRW vs EBS Comparison
Compare BRW & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRW
- EBS
- Stock Information
- Founded
- BRW 1987
- EBS 1998
- Country
- BRW United States
- EBS United States
- Employees
- BRW N/A
- EBS N/A
- Industry
- BRW Trusts Except Educational Religious and Charitable
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- BRW Finance
- EBS Health Care
- Exchange
- BRW Nasdaq
- EBS Nasdaq
- Market Cap
- BRW 333.0M
- EBS 359.3M
- IPO Year
- BRW N/A
- EBS 2006
- Fundamental
- Price
- BRW $8.03
- EBS $7.30
- Analyst Decision
- BRW
- EBS Strong Buy
- Analyst Count
- BRW 0
- EBS 3
- Target Price
- BRW N/A
- EBS $14.33
- AVG Volume (30 Days)
- BRW 222.1K
- EBS 1.4M
- Earning Date
- BRW 01-01-0001
- EBS 08-05-2025
- Dividend Yield
- BRW 15.59%
- EBS N/A
- EPS Growth
- BRW N/A
- EBS N/A
- EPS
- BRW N/A
- EBS N/A
- Revenue
- BRW N/A
- EBS $965,400,000.00
- Revenue This Year
- BRW N/A
- EBS N/A
- Revenue Next Year
- BRW N/A
- EBS $18.88
- P/E Ratio
- BRW N/A
- EBS N/A
- Revenue Growth
- BRW N/A
- EBS N/A
- 52 Week Low
- BRW $7.15
- EBS $4.02
- 52 Week High
- BRW $8.30
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- BRW 61.63
- EBS 61.46
- Support Level
- BRW $8.06
- EBS $6.59
- Resistance Level
- BRW $8.14
- EBS $7.42
- Average True Range (ATR)
- BRW 0.08
- EBS 0.40
- MACD
- BRW -0.00
- EBS 0.06
- Stochastic Oscillator
- BRW 69.70
- EBS 75.76
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.